Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin and dexamethasone for perioperative glycocalyx protection in major abdominal surgery
ACTRN12618000361202Phase 4Completed
- Sponsor
- Austin Health
- Start
- Jul 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of dexamethasone and albumin (human) in endothelial dysfunction and endothelial glycocalyx degradation (EGD) (2 arms), sponsored by Austin Health. Primary endpoint: Plasma syndecan-1 level at 24 hours postoperatively. Started Jul 2018; status: completed.
02
Drugs
dexamethasonealbumin (human)
03
Conditions
endothelial dysfunctionendothelial glycocalyx degradation (EGD)
Beyond the preview
Go deeper on ACTRN12618000361202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000361202.